Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Talen Energy Corp V.TLN


Primary Symbol: TLN

Talen Energy Corporation owns and operates power infrastructure in the United States. The Company produces and sells electricity, capacity, and ancillary services in wholesale power markets in the United States, primarily in PJM and WECC, with its generation fleet principally located in the Mid-Atlantic region of the United States and Montana. The majority of its generation is produced at its zero-carbon nuclear and lower-carbon gas-fired facilities. Its generation capacity is 10,665 megawatts (MW). Its segments include PJM and Other. The PJM segment is engaged in electricity generation, marketing activities, commodity risk and fuel management within the PJM RTO or ISO markets and comprises Susquehanna and Talen’s natural gas and coal generation facilities. Its Other segment includes the operating and marketing activities of Talen Montana’s proportionate share of the Colstrip Units in the WECC market, the operating activities of Nautilus, and other development activities.


NDAQ:TLN - Post by User

Bullboard Posts
Post by Everswanon May 30, 2009 1:50pm
81 Views
Post# 16030017

Drug combo, the new Standard of Care

Drug combo, the new Standard of Care
ASCO 2009, is about personalized medicine.
ASCO 2009, is about finding which drugs goes well for a specific patient
Also ASCO 2009 is about adopting a new strategy; slowing down cancer with a combo mix..

https://www.ajc.com/health/content/shared-auto/healthnews/-lun/627547.html


Again, the above show the promise of combining Avastin and Tarceva, the two dominant cancer drug on the market.


Ras inhibitors can basically be combine with any sort of drug.

This is an article I provided to this board months ago, and now pepmoron, the moron is using it to scare people.
It's dated but most of the science is still valid.
Some speculative aspect of it came true, as you can read onà



https://www.tau.ac.il/lifesci/departments/neuro/members/kloog/documents/blum.pdf


Also, on the last page , the author talk about about a RAS and glycolysis combo as the best mix possible!!! ... Well, that's 232 and 4601 ... ahahhahahah



Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse